Total amount: € 0,00
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536
Online ISSN 1827-1758
XVI CONGRESS DELLA SOCIETÀ ITALIANA DI NEFROLOGIA SEZIONE PIEMONTE-VALLE D’AOSTA
Castello di Rivoli, Rivoli (TO) October 10, 1998
Gonella M., Calabrese G., Scancarello M. *, Mengozzi A. *, Deambrogio P. *
ASL n. 21 - Regione Piemonte Ospedale S. Spirito Casale Monferrato (Alessandria) Servizio di Nefrologia e Dialisi
*Laboratorio Analisi Chimico-Cliniche
Background. Hyperhomocysteinemia is an independent risk factor for cardiovascular diseases, and is a common finding in patients on regular dialysis treatment. Hemodialysis lowers homocysteine plasma levels in variable amounts, and it was also suggested that folic acid and vitamin B12 supplements can reduce such levels. The purpose of the present study was to evaluate homocysteine plasma levels in patients on hemodiafiltration who received vit. B12 and folate supplements such as to keep their plasma levels in the normal range.
Methods. A retrospective study was carried out in a group of 36 patients on hemodiafiltration, who received routinely folate and vit. B12 supplements i.v. Pre-dialysis plasma levels of folate and vit. B12 and pre-postdialysis homocysteine concentration were evaluated. The latter was correlated with other parameters.
Results. The present study confirmed high homocysteine levels in patients on RDT and their reduction due to dialysis, demonstrated a weak negative correlation of pre-dialysis homocysteine with vit. B12 plasma level, but no correlation with folic acid.
Conclusions. This study showed a good efficiency of hemodiafiltration using high permeability membranes on homocysteine remo-val, whereas the negative correlation between folate and homocysteine plasma level was not confirmed.